A 24-week study to evaluate the effect of rilapladib on cognition and cerebrospinal fluid biomarkers of Alzheimer's disease [0.03%]
利拉普拉迪布对阿尔茨海默病患者认知和脑脊液生物标志物影响的24周研究
Gareth Maher-Edwards,Jeni De&#x;Ath,Carly Barnett et al.
Gareth Maher-Edwards et al.
Background: The lipoprotein-associated phospholipase A2 inhibitor (Lp-PLA2), rilapladib (SB659032), is being evaluated as a potential treatment to slow the progression of Alzheimer's disease (AD). ...
Karen Ritchie,Craig W Ritchie,Kristine Yaffe et al.
Karen Ritchie et al.
Introduction: Increasing evidence suggests that Alzheimer's disease (AD) may begin decades before evidence of dementia, indicating that it may be a disorder of midlife rather than old age. ...
Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years [0.03%]
索拉珠单抗临床试验中轻度阿尔茨海默病患者的延迟分析：3.5年
Hong Liu-Seifert,Eric Siemers,Karen C Holdridge et al.
Hong Liu-Seifert et al.
Introduction: Solanezumab is an anti-amyloid monoclonal antibody in clinical testing for treatment of Alzheimer's disease (AD). Its mechanism suggests the possibility of slowing the progression of AD. ...
Stereotactic brain injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer's disease dementia: A phase 1 clinical trial [0.03%]
人脐带血间充质干细胞立体定向脑内注射治疗阿尔茨海默病痴呆的Ⅰ期临床试验
Hee Jin Kim,Sang Won Seo,Jong Wook Chang et al.
Hee Jin Kim et al.
Introduction: We conducted a phase 1 clinical trial in nine patients with mild-to-moderate Alzheimer's disease to evaluate the safety and dose-limiting toxicity of stereotactic brain injection of human umbilical cord bloo...
A phase 2 randomized, controlled trial of the α7 agonist ABT-126 in mild-to-moderate Alzheimer's dementia [0.03%]
ABT-126（一种α7激动剂）治疗轻中度阿尔茨海默病患者 II 期随机对照试验结果
Laura M Gault,Craig W Ritchie,Weining Z Robieson et al.
Laura M Gault et al.
Introduction: The safety and efficacy of the novel α7 nicotinic acetylcholine receptor agonist ABT-126 were investigated in subjects with mild-to-moderate Alzheimer's dementia (AD). ...
Body brain life: A randomized controlled trial of an online dementia risk reduction intervention in middle-aged adults at risk of Alzheimer's disease [0.03%]
身心生活法：一种针对中年阿尔茨海默病高风险人群的线上干预随机对照试验
Kaarin J Anstey,Alex Bahar-Fuchs,Pushpani Herath et al.
Kaarin J Anstey et al.
Objective: To examine the efficacy of body brain life (BBL), a 12-week online dementia risk reduction intervention. Methods: BBL was ev...
Effect of sample size re-estimation in adaptive clinical trials for Alzheimer's disease and mild cognitive impairment [0.03%]
适应性临床试验中样本量重估对阿尔茨海默病和轻度认知障碍的影响
Guoqiao Wang,Richard E Kennedy,Gary R Cutter et al.
Guoqiao Wang et al.
Introduction: The sample size re-estimation (SSR) adaptive design allows interim analyses and resultant modifications of the ongoing trial to preserve or increase power. We investigated the applicability of SSR in Alzheim...
The design and progress of a multidomain lifestyle intervention to improve brain health in middle-aged persons to reduce later Alzheimer's disease risk: The Gray Matters randomized trial [0.03%]
一项针对中年人改善脑健康、减少日后罹患阿尔茨海默病风险的多领域生活方式干预的设计与进展：Gray Matters 随机试验
Maria C Norton,Christine J Clark,JoAnn T Tschanz et al.
Maria C Norton et al.
Introduction: Most Alzheimer's disease (AD) prevention studies focus on older adults or persons with existing cognitive impairment. This study describes the design and progress of a novel pilot intervention, the Gray Matt...
Neural and behavioral substrates of disorientation in mild cognitive impairment and Alzheimer's disease [0.03%]
轻度认知障碍和阿尔茨海默病的定向力损害的行为学及神经行为学基底
Amber Sousa,Jesus J Gomar,Terry E Goldberg
Amber Sousa
Background: The neural and cognitive substrates of measures of orientation as used in clinical trials and examinations have not been comprehensively examined. ...